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Introduction
The discovery and development of antibiotics to treat bac-
terial infections is one of the greatest triumphs of modern 
medicine. However, the exponential increase of antimi-
crobial resistance means that bacterial infections now 
once more pose a major threat to human health [126]. 
The high frequency of re-discovery of known molecules 
thereby frustrates screening efforts, and this necessitates 
new approaches to bolster the antibiotic pipelines [6, 23, 
39, 95]. Filamentous fungi and bacteria of the order of 
Actinomycetales are the major producers of biomedical 
and agricultural natural products, and these microorgan-
isms are responsible for producing the vast majority of 
the known antibiotics [9, 85]. Some two-thirds of all anti-
biotics are produced by actinomycetes, the majority of 
which are sourced by members of the genus Streptomy-
ces. However, this is likely to represent only a tiny por-
tion of the repertoire of total chemical space of bioactive 
compounds that these microorganisms may produce [9, 
85]. Firstly, while the number of filamentous microbes 
in soil and marine environments is enormous, the bulk of 
them resist cultivation in the laboratory and thus escape 
screening and exploitation [53]. Recent work showed that 
enabling growth of these ‘uncultivable’ microorganisms 
might open up a new area of the chemical space of natu-
ral products [68, 129]. Secondly, many natural product 
biosynthetic gene clusters (BGCs) of cultivable microbes 
remain silent during standard laboratory cultivation [10, 
136]. As an example, genome sequencing of actinomy-
cetes revealed that the producing capacity of even the 
best-studied model organisms has been grossly underes-
timated [8, 27, 51, 119]. Thirdly, those gene clusters that 
are expressed, particularly if expression is relatively low 
as compared to other bioactive compounds produced by 
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the same organism, often escape discovery due to the 
very demanding chemical analysis or chromatographic 
purification that is required [94]. New approaches are 
therefore required to exploit the huge unexplored res-
ervoir of bioactive natural products and rejuvenate the 
drug-discovery pipelines.
The preferred method of identifying compounds in com-
plex mixtures is metabolomics, which is a high-throughput 
analytical technique that offers a global analysis of the 
products of all cellular metabolic reactions, regardless of 
the reactions that lead to their production [96]. Spectro-
scopic techniques, and in particular nuclear magnetic reso-
nance (NMR) and mass spectrometry (MS), are applied 
to chemically profile the metabolites that are produced by 
microorganisms. In connection with a wide range of chem-
ometric methods, the metabolic differences among experi-
mental groups are subsequently unraveled by comparison 
[38, 131]. In this review, we discuss ways to enforce fluc-
tuations in the production of bioactive compounds, and the 
application of metabolomics to facilitate uncovering those 
compounds, whereby we zoom in on NMR-based meta-
bolic profiling methods, which are less commonly applied 
in microbial drug discovery.
Approaches to elicit antibiotic production
Genome mining of actinomycetes on average reveals the 
presence of 30–40 secondary metabolite BGCs per spe-
cies [125]. Only a small number of these gene clusters 
has been matched to a natural product. A major problem 
is that many BGCs remain silent or poorly expressed 
under routine screening conditions. If we are to even start 
attempting to visualize these compounds by metabolomics 
approaches, their activation is the first essential step. 
Generic approaches to activate silent antibiotics to uncover 
the hidden chemical diversity include: (i) changing the 
growth media [14, 137]; (ii) inducing antibiotic resistance, 
e.g. to streptomycin [91] or rifampicin [37, 48, 90]; (iii) the 
addition of chemical elicitors, such as N-acetylglucosamine 
[98], γ-butyrolactones [50, 128], or histone deacetylase 
inhibitors [2]; and (iv) microbial cocultivation [11, 49, 
109]. Instead of inducing the production of an antibiotic, 
an interesting alternative may be offered by screening for 
inducible resistance, in particular associated with classes 
of antibiotics that are less frequently identified in classi-
cal screens. Growth on media containing the glycopeptide 
vancomycin was used to select actinomycetes that produce 
(and are therefore resistant to) glycopeptide antibiotics. 
Subsequent phylogeny-based screening based on specific 
biosynthetic genes led to the identification of the novel gly-
copeptide antibiotic pekiskomycin [114].
In terms of the activation of antibiotic production, a con-
cept study was recently done using a collection of some 
800 strains that were grown under 40 different growth con-
ditions and then assayed for changes in the production of 
antimicrobial activity against the so-called ESKAPE patho-
gens [137]. This showed that many strains that fail to pro-
duce antibiotics under routine growth conditions, produce 
bioactivities that inhibit the growth of MDR pathogens 
under specific nutritional conditions or after addition of 
elicitors [137].
Harnessing the regulatory mechanisms that control 
antibiotic biosynthesis
To develop new directed approaches, it is imperative that 
we better understand the underlying regulatory networks. 
The regulation of antibiotic production involves multiple 
regulatory cascades and networks. Here, we will guide 
the reader with some general principles gleaned from the 
model organism Streptomyces coelicolor; for more exten-
sive reviews on the control of antibiotic production we 
refer the reader elsewhere [13, 69, 100, 120].
Antibiotic BGCs specify biosynthesis and modifica-
tion, resistance, transport and pathway-specific control. 
The best-studied example of cluster-encoded, pathway-
specific activators is that of the Streptomyces antibiotic 
regulatory proteins (SARPs). SARPs typically bind to 
direct repeats in promoter regions of biosynthetic genes, 
thereby activating transcription of some or all of the anti-
biotic biosynthetic genes in the cluster [127]. In S. coeli-
color, the pathway-specific regulatory genes actII-ORF4, 
cdaR and redD encode the SARPs for actinorhodin (ACT), 
calcium-dependent antibiotic (CDA) and undecylprodigi-
osin (RED) production, respectively. Of these, actII-ORF4 
and redD have been extensively studied. Deletion of these 
genes abolishes the production of actinorhodin or unde-
cylprodigiosin, respectively [36], and their transcription 
is activated in a growth phase-dependent manner [4, 113]. 
Interestingly, positioning redD behind a developmental or 
nitrogen-responsive promoter is sufficient to produce unde-
cylprodigiosin in aerial hyphae or bring it under nitrogen 
control, respectively, which suggests a lack of downstream 
control [122]. Hence, one effective approach to activate 
gene clusters is overexpression of their activator genes, but 
this involves genetic manipulation which is not amenable 
to high-throughput approaches.
Recent years have underlined the importance of global 
regulators as a higher order regulatory network, and their 
possible application for the activation of antibiotic produc-
tion. Many pleiotropic regulators characterized so far are 
required only under specific environmental conditions [12, 
121]. The nutrient sensory GntR-family regulator DasR 
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controls among others aminosugar metabolism and transport, 
the chitinolytic system and antibiotic production [21, 22, 26, 
97, 98, 112]. DasR is a highly pleiotropic regulator, as dem-
onstrated by recent systems biology analysis of chitin- or 
N-acetylglucosamine-induced cultures of S. coelicolor [84, 
110]. DasR directly controls the transcription of actII-ORF4 
and redD as well as redZ, a response regulator required for 
the activation of redD and thus of undecylprodigiosin pro-
duction [98]. Systems-wide DNA binding experiments using 
ChIP-chip analysis revealed that in S. coelicolor DasR likely 
controls all pathway-specific activator genes [110], but this 
appears to be more an exception than a rule. The activity of 
DasR is modulated by metabolic derivatives of N-acetylglu-
cosamine, and addition of this amino sugar to the culture 
media activates antibiotic production in several actinomy-
cetes, including cryptic antibiotics [98].
Interesting cross-talk is seen for DasR with other higher 
order antibiotic regulators. One is the TetR-family regula-
tory protein AtrA that in S. coelicolor is required for the 
transcription of actII-ORF4 [118] and in S. griseus of strR, 
the pathway-specific activator gene of streptomycin pro-
duction [47]. The antibiotic activating role of AtrA may 
be widespread, as suggested by recent data that AtrA also 
controls biosynthesis of the important lipoglycopeptide 
antibiotic daptomycin in Streptomyces roseosporus [76]. 
AtrA is controlled by the level of phosphate and repressed 
by the PhoRP system [101]. AtrA activates development 
[60] as well as N-acetylglucosamine import [88], and thus 
antagonizes the repressing activities of DasR, whereby 
the metabolic balance likely plays a deciding role on the 
net outcome. Further complexity is offered by Rok7B7, a 
member of the ROK family of proteins, which are predomi-
nantly sugar regulatory proteins and sugar kinases, includ-
ing glucose kinase [73, 115]. Rok7B7 also pleiotropically 
affects primary and secondary metabolism, and is like AtrA 
required for actinorhodin production [79, 111]. Recent evi-
dence suggests that Rok7B7 may be activated by a deriva-
tive of the C5 sugar xylose [111].
Other pleiotropic antibiotic regulators involved in the 
control of actII-ORF4 are the large SARP-family regula-
tor AfsR and the phosphate regulator PhoP. AfsR derives 
its name from a putative relationship to synthesis of the 
hormone-like signaling molecule A-factor, belonging to 
the γ-butyrolactones. The A-factor-responsive AdpA con-
trols the onset of development and antibiotic production 
in S. griseus [46, 116], but the precise relationship with 
AfsR (if any) so far remains unresolved. In S. coelicolor, 
AfsR is conditionally required for Act and Red production 
[36] and its control is somehow transmitted through con-
trol of the small downstream gene afsS, thereby activating 
its transcription [67]. While the precise function of afsS is 
unclear, similarly to AtrA, its pleiotropic and positive effect 
on antibiotic production makes it an attractive target for 
the activation of antibiotic production. PhoP represses acti-
norhodin production in response to phosphate [106], and it 
may also relay its control via afsS [101] These are exam-
ples to highlight the complexity of the control of antibiotic 
production, whereby an astonishing number of around 15 
regulatory proteins have been shown to control actII-ORF4 
alone [121]. Improved understanding of these multiple and 
intertwined regulatory networks will allow scientists to 
design new approaches to activate poorly expressed BGCs.
Connecting eliciting approaches 
to metabolomics‑driven lead discovery
In the framework of this review, the activation of gene 
expression is important to activate silent gene clusters and 
particularly to achieve significant fluctuation of the produc-
tion of (cryptic) antibiotics and thus differential bioactiv-
ity between cultures; this serves as enabling technology for 
statistical correlation between a bioactivity of interest and 
the responsible (sought-after) compounds. Having estab-
lished such differential expression, the next challenge is to 
efficiently identify the induced antimicrobial compounds 
against a background of an inevitably highly complex 
metabolome matrix.
Metabolomics is an effective tool for facilitating the 
discovery of new antibiotics, because it allows the multi-
variate comparison of active and inactive metabolic sam-
ples, highlighting particularly the differentially produced 
compounds, which serve as potential biomarkers, thereby 
avoiding chemical redundancy in the very early stage [59, 
63, 93]. Integrating metabolomics approaches with new 
eliciting strategies should allow scientists to streamline 
their drug-discovery pipeline, so as to prioritize novel mol-
ecules over repeated (and frustrating) isolation of known 
molecules. A schematic representation of a feasible anti-
biotics discovery pipeline based on NMR-based metabo-
lomics is presented in Fig. 1. Compounds can be readily 
identified in complex biological matrices without time-con-
suming chromatographic separation, further aided by 2D 
NMR experiments. In the next section, we detail some of 
the NMR techniques that are most appropriate for metabo-
lomics approaches.
Metabolomics of natural products based on NMR 
spectroscopy
NMR techniques that are most frequently used in NMR 
metabolomics are 1J-resolved, COSY, TOCSY, HSQC, and 
HMBC [58, 59, 74, 89]. 1H NMR signals corresponding 
to molecules that exist in both the active and the inactive 
groups are discarded based on lack of statistical relevance 
[105]. Chemometric analysis is then used for further data 
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mining of the 1H NMR data, extracting information that is 
intractable to visual detection. In principle, the methodol-
ogy of NMR measurements, spectral data preprocessing, 
and multivariate data analysis basically follow a protocol 
that was originally designed for analysis of plant metabo-
lites [58]. The 1H NMR signals correlated with the better 
bioactivity and separation of the active from the inactive 
groups are used as probing tools for NMR-guided isola-
tion of the sought-after bioactivity. Advantages of NMR-
based over MS-based (LC–MS or GC–MS) metabolomics 
are: (i) the chemical shifts and splitting patterns of proton 
resonance data provide partial structural information that 
allows early assessment of the type of compound causing 
the bioactivity, thus aiding in avoiding redundancy; (ii) 
the analysis of crude mixtures can be done in very short 
time (in the order of minutes), with high signal robustness 
(i.e. minimum technical variation), so as to guide scien-
tists in a medium- to high-throughput environment. These 
advantages should be weighed against the lack of true 
high-throughput application, which is a key selling point 
of MS-based approaches. As soon as the major interfer-
ing signals are removed from the NMR spectra, the mate-
rial (even if not yet pure) is likely of sufficient quality for 
full structure elucidation. In some cases, structural elucida-
tion of unknown compounds is challenging, especially for 
those entities with unprecedented molecular scaffold. Two-
dimensional NMR (2D NMR) techniques have formed the 
foundation of most contemporary approaches for structure 
elucidation [16], allowing assembly of the molecular archi-
tecture by defining atom-to-atom connectivity. In general, 
NMR-based metabolomics uses a combination of 2D NMR 
techniques for deconvoluting metabolites in congested 
mixtures, namely J-resolved, 1H-based 2D (COSY and 
TOCSY), 13C-based 2D NMR (HSQC and HMBC) [16]. 
J-resolved solves the signal purity of 1H NMR by showing 
splitting pattern with coupling constants in F2 axis which 
requires for chemical structures of corresponding signals. 
COSY and TOCSY give information of 1H connectivity 
within the same molecule. Along with the connectivity, the 
1H-based COSY and TOCSY also help signal identification 
in overlapped regions. Many signals are overlapped which 
obscures some of the peaks in the mixture, but these can be 
deconvoluted by the correlations in the 2D NMR spectra. 
13C-related spectra such as HSQC and HMBC give more 
detailed structural information, particularly for the carbon 
skeleton. Although important for identifying the carbon 
skeleton of organic compounds, 13C-NMR is rarely applied 
in NMR-based metabolomics because of the low abun-
dance of 13C in nature and its long relaxation time, and also 
because 13C broad-band decoupling cannot be used quanti-
tatively. HSQC and HMBC are therefore primarily applied 
to support the 1H NMR data.
Deciphering the structure of organic molecules by 
using conventional routine suites, based on for example 
J-resolved-COSY (or TOCSY), HSQC and HMBC [87] 
often gives rise to misassignment. This partly arises from 
the inherent challenges of differentiating two-bond het-
eronuclear (H ⇢ C, 2JCH) correlations from three-bond 
correlations (3JCH) in the HMBC spectrum. In addition, as 
HMBC normally just provides 2JCH and 
3JCH but rarely 
4JCH 
correlations, structure elucidation becomes progressively 
challenging the more molecules become proton-deficient 
[104]. To address these problems, many other approaches 
have been tried such as combined HSQC-TOCSY [61]. 
Researchers from Merck proposed that adequate sensitiv-
ity double-quantum (1, n-ADEQUATE) NMR spectros-
copy should be reconsidered as a complement for HMBC 
in structure elucidation [77]. 1,1-ADEQUATE exclusively 
presents 1JCC correlations and can help distinguish 
2JCH 
from 3JCH correlations in the HMBC spectrum, which 
would be a powerful method for determining the proton-
rich small molecules by using a combination of 1,1-ADE-
QUATE + HMBC [19, 83]. 1, n-ADEQUATE experiments 
predominantly yield homonuclear 3JCC correlations (equal 
to 4JCH) that are difficult to obtain with HMBC NMR. This 
feature makes 1, n-ADEQUATE a complement for HMBC 
in defining proton-deficient structures, such as a large group 
of aromatic polyketides (PKS) produced by actinomycetes 
Fig. 1  A pipeline for the discovery of antibiotics produced by actino-
mycetes based on NMR-based metabolomics. Strains are subjected 
to eliciting approaches to activate the production of poorly expressed 
antimicrobials, followed by NMR-based metabolomics to identify the 
bioactive molecules. 1H NMR profiling of active and inactive groups, 
aided by 2D NMR, allows dereplication of known molecules and che-
mometric methods then correlate proton signals in the active fractions 
to the bioactive compound(s)
Fig. 2  Diagram of HMBC (blue anticlockwise semi-circle arrows), 
and inverted 1JCC 1, n-ADEQUATE correlations by using the 
proton-deficient alkaloid staurosporine as an example. The skel-
eton of this model compound can be unequivocally assigned by 
HMBC + inverted 1JCC 1, n-ADEQUATE strategy. In inverted 1JCC 
1, n-ADEQUATE, 1JCC correlations are shown as red clockwise semi-
circle arrows, while important 3JCC correlations are shown as green 
clockwise semi-circle arrows
◂
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[17, 83]. Furthermore, newly developed inverted 1JCC 1, 
n-ADEQUATE spectroscopy allows the integration of 
1,1-ADEQUATE and 1, n-ADEQUATE information in a 
single spectrum, while they remain distinguished by plot-
ting the output in different colors (Fig. 2) [78].
Though NMR spectroscopy is undoubtedly powerful in 
the structure elucidation, it works better on pure organic 
compounds, as otherwise signal-overlapping issues come 
into play. To address this, chromatography-hyphenated 
NMR (HPLC-NMR) has been introduced into metabolic 
analysis [130]. The major advantages of on-flow HPLC-
NMR lie in the real-time access to structure information 
of chromatographic peaks by using NMR spectrometers 
as detector [75]. To balance the inherent lower sensitivity 
of NMR spectra and the limited injection volume onto the 
HPLC unit, solid-phase-extraction (SPE) is coupled to trap 
the analytes onto an identical SPE cartridge when repeated 
HPLC analysis, followed by final elution with a deuterated 
solvent into miniaturization tube for NMR analysis [103]. 
By using this LC-SPE-NMR approach [64, 108], compre-
hensive structural information about chemical composi-
tion of crude extracts can be obtained online, thus enabling 
early and prospective assessment of the valuable com-
ponents of an extract or fraction [52]. Furthermore, when 
integrating MS into the system, like LC-DAD-SPE-MS-
NMR instrumentation [33, 70], the architecture of novel 
compounds can be elucidated de novo and online without 
laborious purification of the analyte(s) from its highly com-
plex matrix.
Connecting genotype to chemotype: integrating 
genomics with metabolomics
Before looking at applications of metabolomics to identify 
novel compounds, in this section we will look into how 
metabolomics may aid in connecting a natural product of 
interest to its BGC. This is a crucial step as it facilitates 
molecular approaches such as directed mutagenesis, over-
expression of pathway-specific regulators and heterologous 
expression. Furthermore, identification of the gene cluster 
is often required for determining the precise biosynthetic 
pathway.
Next-generation sequencing (NGS) technologies have 
uncovered the genetic architecture of thousands of BGCs, 
and this has revolutionized the drug-discovery approaches 
[24]. Exploiting this rapidly increasing source of informa-
tion, a recent network analysis of the phylogeny and dis-
tribution of BGCs in microbial genomes revealed a vast 
number of yet underexplored genetic resources, belonging 
to many hundreds of gene cluster families [20].
Gene clusters such as those for PKS or nonribo-
somal peptides (NRPS) are readily identified using 
bioinformatics, and to some extent the domain structures of 
the biosynthetic proteins allows prediction of the molecule 
that they specify [5, 66]. In recent years, excellent bioin-
formatics packages have been developed for the identifi-
cation of BGCs. These include antiSMASH (ANTIbiotics 
& Secondary Metabolite Analysis SHell [81] and SMURF 
(Secondary Metabolite Unknown Regions Finder), as well 
as packages that enable the identification of biosynthesis 
genes for specific subclasses of NPs (reviewed in [34] ). 
Examples are SBSPKS (Structure Based Sequence Analy-
sis of Polyketide Synthases) for polyketide BGCs [3], 
NRPSPredictor for NRPS gene clusters [99] and BAGEL 
for the identification of biosynthetic clusters for bacterioc-
ins and lantibiotics [28].
From genotype to chemotype: bioinformatics‑guided 
natural product discovery
How can we determine whether the compound that is 
derived from a given BGC is novel (genotype to chemo-
type) or, conversely, link a natural product of interest to its 
gene cluster (chemotype to genotype)? The genotype-to-
chemotype roadmap (Fig. 3a) [56, 57] provides a glimpse 
of ‘hidden treasures’, e.g. aided by the exploitation of 
pathway-specific regulators [40, 65] or via heterologous 
gene expression [7, 92]. Metagenomic libraries from envi-
ronmental samples thereby allow scientists access to the 
‘dark matter’, namely the vast biosynthetic potential of 
uncultivable microbes [15, 54]. However, an intrinsic dis-
advantage of genome-based bioprospecting is that current 
technologies target a single BGC at the time, which is time-
consuming, while the discovery efficiency is low as it is 
very difficult to prioritize ‘promising’ gene clusters. After 
all, if a gene cluster appears novel, it does not mean that 
the compound has not already been identified in HT screen-
ing regimes in the pre-genomic era. We predict, however, 
that synthetic biology and heterologous expression of gene 
clusters will soon become part of a more automated envi-
ronment, which would make these approaches much more 
feasible. In addition, approaches directed at the (heterolo-
gous) expression of gene clusters depend on the functional 
analysis of biosynthetic enzymes and/or detection of intact 
clusters, while biosynthetic reactions may be catalyzed by 
enzymes that are not encoded by the gene cluster itself and/
or by enzymes with low specificity [102], or are catalyzed 
non-enzymatically [80, 132]. Indeed, metabolites are the 
end products of many cellular processes, so that the bioac-
tive end product is not necessarily specified by individual 
genes or clusters [96].
In the case of intertwined metabolic and biosynthetic 
pathways giving rise to a single compound, targeted 
genomic approaches lose their effectiveness [117, 124, 
132]. In such cases, metabolomic approaches are required 
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to bridge the gap between bioinformatics-driven gene clus-
ter analysis and NP discovery [30, 62]. The fundamental 
principle is based on the fact that structurally related NPs 
are typically characterized by similar MS/MS fragmenta-
tion patterns. The MS/MS structural relatedness among 
molecules can be detected in an automated manner, and can 
subsequently generate a molecular network wherein ana-
logues cluster together. In this way, known structures and 
“known unknowns” can be identified in extracts, offering 
an effective dereplication strategy and a way of prioritizing 
novel compounds [134].
From chemotype to genotype: metabolomics to identify 
biosynthetic gene clusters
MS/MS analysis allows the detection of “structural unit 
tags” or building blocks whose biosynthesis needs specific 
enzymes bearing substrate specificity. Candidate genes can 
be used as query against the genome databases to locate 
the target gene cluster for the compound(s) of interest. 
MS-based metabolomics in conjunction with molecular 
networking builds up a chemotype-to-genotype roadmap 
(Fig. 3b) [44, 56, 57, 62] for NP discovery, directly linking 
secondary metabolites to their corresponding gene clusters. 
Examples for this concept include peptidogenomics [56, 
86], glycogenomics [57] and natural product proteomining 
[43]. Peptidogenomics is an MS-based genome-mining 
method that links peptide natural products to their BGCs 
through iteratively matching tandem MS (MSn) sequence 
tagging with genomics-derived peptide structures [56], 
supported by software automation packages such as the 
recently developed Pep2Path [82]. For an excellent review 
of peptidogenomics techniques and their application we 
refer the reader elsewhere [62]. Glycogenomics is a chem-
otype-to-genotype approach for fast characterization of gly-
cosylated natural products (GNPs) and their biosynthetic 
pathways. Tandem mass spectrometry (MSn) allows rapid 
identification of the structural information of sugar substit-
uents of GNPs in microbial metabolic extracts [32, 45]. The 
biosynthesis of certain sugars need specific enzymes; as an 
example, genes for forosamine production encode 2,3- and 
3,4-dehydratases, 3-ketoreductase, aminotransferase and 
N,N-dimethyltransferase. Applying the bacterial sugar bio-
synthetic knowledge, MSn-characterized glycosyl groups 
can be matched to corresponding glycosylation genes. In 
microbial genomes, the glycosylation-associated biosyn-
thetic genes are usually co-clustered with those for a wide 
range of aglycones. Programs such as antiSMASH are spe-
cifically designed with the identification of such signature 
BGCs in mind. The relevant aglycone biosynthetic genes 
are then identified, which in turn guides further isolation 
and structural identification of glycoconjugates by applying 
Fig. 3  General workflows for genotype-to-chemotype (a) and chemotype-to-genotype (b) genome mining for natural product discovery
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knowledge of the aglycone-specific BGC. As aglycones 
could be any type of structural scaffolds, for sugar-modi-
fied NPs, glycogenomics has an advantage over peptidog-
enomics. This technique therefore expands the applicability 
of MS-guided genome mining for different classes of NPs, 
such as nonribosomal and ribosomal peptides, PKS, terpe-
nes, and alkaloids [32]. Furthermore, since glycosylated 
products are produced via the decoration of an aglycone, 
which is often bioactive by itself, we envisage that glycog-
enomics can be extended to discover even non-glycosylated 
NPs that serve as intermediates for final GNPs.
Natural product proteomining is based on the concept 
that gene cluster expression profiles correlate directly to 
the level of the corresponding natural product [43]. When 
growth conditions are chosen such that a bioactivity of 
interest is differentially produced, e.g. high under some 
conditions and intermediate or not at all in others, statis-
tical correlation between bioactivity (metabolomics) and 
gene expression profiles (proteomics, RNAseq) will allow 
prioritizing those gene clusters with the optimal match. 
Since the metabolomics will also provide clues on the type 
of molecule, evidence of the BGC responsible for the prod-
uct of interest can thus be obtained, with the predictive 
value depending on the number of candidate BGCs present 
in the genome and the number of samples analyzed [43]. 
The concept of metabolomics aiding genomics in finding 
new NPs is also exemplified by the case of myxoprinco-
mide from the Myxococcus xanthus [25]. Initially, 13 BGCs 
in M. xanthus DK1622 were found for which the metabo-
lites remained elusive. After targeted inactivation of these 
cryptic gene clusters, MS-based metabolomics was applied 
to pairwise compare extracts of mutants and the wild-type 
strain, highlighting the subtle metabolic differences by sta-
tistical filtering. Thus, a metabolite with molecular formula 
C45H76N10O16 was assigned to a NRPS/PKS hybrid gene 
cluster and identified as a molecule with the unprecedented 
structural skeleton of myxoprincomide. Gene knockout/
untargeted metabolomics strategy could also facilitate dis-
covery of intermediates and/or new side products of bio-
synthesis pathway, as exemplified by characterization of 
2-alkyl-4,5-dihydrothiazole-4-carboxylates from Pseu-
domonas aeruginosa [55, 123]. Comparison of the extra-
cellular metabolome of P. aeruginosa pch mutants with that 
of the wild-type strain identified 198 secondary metabolites 
regulated by these pathway-specific pch genes. Therefore, 
perturbation of the expression of global or pathway-specific 
regulators followed by metabolomics is a promising strat-
egy to rapidly connect molecules to genes or gene clusters.
Experimental approaches based on NMR 
metabolomics
As explained above, metabolomics approaches allow elu-
cidating the nature of poorly bioactive molecules in com-
plex mixtures, and for this achieving differential production 
of the bioactivity of interest is a key step. Such fluctua-
tion may be achieved by among others different culturing 
conditions, inducing drug-resistance or by co-culturing 
[38, 131]. NMR-based metabolomics is very common 
for identifying plant NPs, but has yet seen relatively little 
application in microbial drug discovery. A general scheme 
is presented in Fig. 1. We recently applied NMR-based 
metabolomics for the mining of novel soil isolates with 
promising antibiotic-producing potential, of which we pro-
vide a few examples here for illustration purposes. To iden-
tify a bioactivity produced by the soil isolate Streptomyces 
sp. MBT70, the strain was grown in media supplemented 
Fig. 4  Chemical structures of 
the compounds mentioned in 
the final section of the review 
(“Experimental approaches 
based on NMR metabolomics”)
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with different additives followed by 1H NMR spectroscopy 
and statistical comparison of the extracts by partial least 
square modeling-discriminant analysis (PLS-DA). A main 
discriminator between bioactive and inactive cultures was 
a signature H-5 residue belonging to a naphthoquinone. 
Further HPLC fractionation targeting naphthoquinones 
then led to the isolation and identification of juglomycin C 
amide (Fig. 4) [43]. The generation of streptomycin resist-
ant (StrR) mutants in soil isolate Streptomyces sp. MBT28 
resulted in the specific activation of a bioactive compound, 
which was subsequently identified by comparing the active 
(StrR-induced) and non-active fractions by 1H NMR and 
statistical analysis by projection to latent structures (PLS); 
this allowed correlation of the enhanced bioactivity to a 
set of distinctive aromatic signals. NMR-guided separa-
tion by tracking characteristic 1H NMR signals as probes, 
resulted in the characterization of the isatin-type antibiotic 
7-prenylisatin (our unpublished data). As a third exam-
ple, co-cultivation of the filamentous model microbes S. 
coelicolor and Aspergillus niger substantially influenced 
their NPs profiles. NMR spectroscopy of extracts obtained 
from the separate strains and the coculture combined with 
multivariate data analysis revealed diketopiperazine-type 
compounds like cyclo(Phe-Phe) (Fig. 4), which were exclu-
sively produced by A. niger when grown in co-culture with 
S. coelicolor [133].
1H NMR based profiling also finds its application in 
lead discovery. Quinn and coworkers integrated solid phase 
extraction (SPE) with NMR fingerprinting. An extract 
library was prepared featuring lead-like enhanced (LLE) 
fractions selected on the basis of favorable physicochemi-
cal properties [18], and this LLE library was subsequently 
profiled by 1H NMR spectroscopy to present the struc-
tural information of the small molecules contained in the 
library. In this way, the complicated and overlapping 1H 
NMR spectra typical of crude extracts were avoided by 
prefractionation, facilitating the detection of minor com-
pounds. Using the proton signals as tracking signals for 
NMR-guided isolation, an unprecedented scaffold of iotro-
chotazine A was identified in LLE-fractionated extracts 
from sponges [41] and low-abundant venulosides C and D 
(Fig. 4) in extracts from plants [42].
Fig. 5  In vivo 1H NMR spectroscopy monitors NDM-1 activity in 
living Escherichia coli cells. Cyclic amide ring in β-lactam antibiotic 
meropenem is hydrolyzed under catalysis of enzyme NDM-1. The 
1H NMR chemical shifts of four characteristic methyls (green) in the 
substrate accordingly move upfield in the hydrolytic product (red). 
This reaction can be monitored in real-time without disturbing the 
experimental system
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An important class of NPs in the fight against antibiotic 
resistance is that of resistance inhibitors. Penicillins are still 
the most administered antibiotics [29, 107], but resistance 
caused by β-lactamases was discovered almost as soon as 
the antibiotic itself [1] and has become a major problem 
for their clinical application [126]. The combined use of 
β-lactam antibiotics together with β-lactamase inhibitors 
is exemplified by the combination of amoxicillin and cla-
vulanic acid, marketed as Augmentin® [31, 35]. A target-
based in-cell NMR approach was recently proposed for use 
in high-throughput screening approaches to identify resist-
ance inhibitors with activity against a specific β-lactamase 
[71]. The New Delhi metallo-β-lactamase (NDM-1), which 
opens the cyclic amide ring in β-lactams antibiotics [135], 
was monitored in real time in E. coli cells by 1H NMR 
spectroscopy [72]. The approach is summarized in Fig. 5. 
The chemical shifts of four characteristic methyl groups are 
different between the substrate meropenem and its NDM-
1-degraded product, which was used as a reporter of the 
lytic reaction. Inhibition of NMD-1 enzymatic activity was 
readily detected since the characteristic methyl groups of 
meropenem remain unshifted in the 1H NMR spectrum. 
NMR-guided fractionation was then applied to trace the 
responsible antibiotic adjuvants in the active fractions.
Conclusions
In a time where dereplication is one of the major challenges 
in screening efforts, metabolomics offers an effective strat-
egy to prioritize novel molecules produced by microorgan-
isms. Combination of eliciting strategies with comprehen-
sive chemometric comparison of secondary metabolomes 
and genomics is an excellent alternative over traditional HT 
approaches. Metabolomics thereby complements (meta-)
genomics and synthetic biology approaches in the mining 
of producing organisms, in particular for poorly expressed 
(cryptic) molecules. In addition, connecting chemotype to 
genotype and vice versa is important to facilitate molecu-
lar approaches and to accelerate unraveling of the biosyn-
thetic pathway, and thus enable metabolic engineering and 
upscaling. Also taking the huge promise of the unculturable 
microorganisms into account, it is clear that natural prod-
uct discovery is far from an echo from the past. Instead, 
as noted by many scientists worldwide, we may well be 
witnessing a new era of drug discovery, where many dif-
ferent disciplines such as genomics, metabolomics, bioin-
formatics, synthetic biology, ecology, chemical biology and 
industrial screening come together to meet the drug-discov-
ery challenges and deliver new solutions to treat infectious 
diseases associated with drug resistance.
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